Lv4
790 积分 2026-03-16 加入
Pharmacokinetic models for first-in-human dose selection of immune-activating products in oncology
14小时前
已完结
Strategies and Recommendations for Using a Data‐Driven and Risk‐Based Approach in the Selection of First‐in‐Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Assessment
14小时前
已完结
Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia
14天前
已完结
Impact of target‐mediated drug disposition on hetrombopag pharmacokinetics and pharmacodynamics in Chinese healthy subjects and patients with chronic idiopathic thrombocytopenic purpura
14天前
已完结
Pharmacokinetic and Pharmacodynamic Modeling of Pegylated Thrombopoietin Mimetic Peptide (PEG‐TPOm) After Single Intravenous Dose Administration in Healthy Subjects
14天前
已完结
Romiplostim Dose Response in Patients With Immune Thrombocytopenia
14天前
已完结
Pharmacokinetic and pharmacodynamic modeling of romiplostim in animals
14天前
已完结
Pharmacodynamic modeling of thrombopoietin, platelet, and megakaryocyte dynamics in patients with acute myeloid leukemia undergoing dose intensive chemotherapy
14天前
已完结
Basic pharmacodynamic models for agents that alter production of natural cells
14天前
已完结
Concentration-Response Modeling of ECG Data From Early-Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk - Experience From the Development Program of Lemborexant
20天前
已完结
皖公网安备34019202002308
